Skip to main content

Climb Bio to Host Virtual Investor Event on October 15, 2024

Written by Customer Service on . Posted in Public Companies.

WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio’s management team and an external expert who will provide an update to the investment community on the Company’s strategy and focus on developing therapeutics for immune-mediated diseases.

Climb Bio’s virtual investor event will include presentations from Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer, Stephen Thomas, Ph.D., Member of Climb Bio’s Board and Co-founder of Tenet Medicines, Jan Hillson, M.D., Senior Clinical Advisor, Nishi Rampal, M.D., Senior Vice President, Clinical Development, and Brett Kaplan, M.D., Chief Operating Officer as well as presentations from a key opinion leader, Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center.

The event will provide an in-depth review of Climb Bio’s lead asset, budoprutug, an anti-CD19 monoclonal antibody that is designed to treat a broad range of immune-mediated diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy and has demonstrated B-cell depletion in early clinical trials.

Register for the event here.

A live webcast of the event, as well as a replay, will be available under “Events and Presentations” in the Investors section of the Company’s website: climbbio.com

About Climb Bio, Inc.
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.

Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843

Media
Jon Yu
ICR Westwicke
jon.yu@westwicke.com
475-395-5375

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.